Biogen hemophilia nod puts Baxter's to-be-spun-off biopharma unit on notice
31.03.2014 / Fierce Pharma
Biogen Idec now has FDA approval for Alprolix, the first in a new wave of long-acting hemophilia treatments on their way to market. For Biogen, the thumbs-up is an opportunity to grab market share with a hemophilia B product that works three times as long as current clotting factors. But what will the ensuing market battle mean for Baxter?